Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,003 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R, Diverio D, Jones K, Aslett H, Batson E, Rennie K, Angell R, Clark RE, Solomon E, Lo-Coco F, Wheatley K, Burnett AK. Grimwade D, et al. Among authors: patel y. J Clin Oncol. 2009 Aug 1;27(22):3650-8. doi: 10.1200/JCO.2008.20.1533. Epub 2009 Jun 8. J Clin Oncol. 2009. PMID: 19506161
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, Patel Y, Guy C, Gilkes A, Milligan DW, Goldstone AH, Prentice AG, Wheatley K, Linch DC, Gale RE. Burnett AK, et al. Among authors: patel y. Blood. 2010 Feb 4;115(5):948-56. doi: 10.1182/blood-2009-08-236588. Epub 2009 Nov 12. Blood. 2010. PMID: 19965647 Free article. Clinical Trial.
Assessment of Minimal Residual Disease in Standard-Risk AML.
Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y, Bhudia N, Farah H, Mason J, Wall K, Akiki S, Griffiths M, Solomon E, McCaughan F, Linch DC, Gale RE, Vyas P, Freeman SD, Russell N, Burnett AK, Grimwade D; UK National Cancer Research Institute AML Working Group. Ivey A, et al. Among authors: patel y. N Engl J Med. 2016 Feb 4;374(5):422-33. doi: 10.1056/NEJMoa1507471. Epub 2016 Jan 20. N Engl J Med. 2016. PMID: 26789727 Free article. Clinical Trial.
Genetic risk factors underlying white matter hyperintensities and cortical atrophy.
Patel Y, Shin J, Sliz E, Tang A, Mishra A, Xia R, Hofer E, Rajula HSR, Wang R, Beyer F, Horn K, Riedl M, Yu J, Völzke H, Bülow R, Völker U, Frenzel S, Wittfeld K, Van der Auwera S, Mosley TH, Bouteloup V, Lambert JC, Chêne G, Dufouil C, Tzourio C, Mangin JF, Gottesman RF, Fornage M, Schmidt R, Yang Q, Witte V, Scholz M, Loeffler M, Roshchupkin GV, Ikram MA, Grabe HJ, Seshadri S, Debette S, Paus T, Pausova Z. Patel Y, et al. Nat Commun. 2024 Nov 4;15(1):9517. doi: 10.1038/s41467-024-53689-1. Nat Commun. 2024. PMID: 39496600 Free PMC article.
1,003 results